Cited by 133Extracellular vesicles in diseaseCancer Genomics and DiagnosticsProstate Cancer Treatment and Research

Extracellular vesicles as a source of prostate cancer biomarkers in liquid biopsies: a decade of research

Open access
Ramirez-Garrastacho, Manuel, Bajo-Santos, Cristina, Line, Aija, Martens-Uzunova, Elena S., de la Fuente, Jesus Martinez, Moros, Maria, Soekmadji, Carolina, Tasken, Kristin Austlid +1 more·2022·British Journal of Cancer

Abstract

Prostate cancer is a global cancer burden and considerable effort has been made through the years to identify biomarkers for the disease. Approximately a decade ago, the potential of analysing extracellular vesicles in liquid biopsies started to be envisaged. This was the beginning of a new exciting area of research investigating the rich molecular treasure found in extracellular vesicles to identify biomarkers for a variety of diseases. Vesicles released from prostate cancer cells and cells of the tumour microenvironment carry molecular information about the disease that can be analysed in several biological fluids. Numerous studies document the interest of researchers in this field of research. However, methodological issues such as the isolation of vesicles have been challenging. Remarkably, novel technologies, including those based on nanotechnology, show promise for the further development and clinical use of extracellular vesicles as liquid biomarkers. Development of biomarkers is a long and complicated process, and there are still not many biomarkers based on extracellular vesicles in clinical use. However, the knowledge acquired during the last decade constitutes a solid basis for the future development of liquid biopsy tests for prostate cancer. These are urgently needed to bring prostate cancer treatment to the next level in precision medicine.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41416-021-01610-8

Cites

241 of 241 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The challenge of isolating EVs by biogenesis arises from the shared biomarkers and overlaps in size among the various EV subtypes.

    “The challenge arises from the shared biomarkers and overlaps in size among the various EV subtypes [124].”

    From Extracellular vesicles as nanotheranostic platforms for targeted neurological disorder interventions (2024) · cites this paper as [124]

    The Background section (“Extracellular vesicles”; page unavailable) says EV subtypes have overlapping size ranges and that current isolation methods cannot accurately separate them. The methodological section describes EV-surface markers used for isolation, but does not establish that shared biomarkers among subtypes cause this difficulty. (LLM, conf=0.84)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

2 of the 243 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

  1. [5]De Angelis G, Rittenhouse HG, Mikolajczyk SD. Blair Shamel, L., Semjonow, A. Twenty years of PSA: from prostate antigen to tumor marker. Rev Urol. 2007;9:113–23. PMC2002501 17934568

Cited by

Sorted by citations

Authors
Ramirez-Garrastacho, M., Bajo-Santos, C., Line, A., Martens-Uzunova, E. S., de la Fuente, J. M., Moros, M., Soekmadji, C., Tasken, K. A., & Llorente, A.
Affiliations
  • Latvian Biomedical Research and Study Centre (LV)
  • The University of Queensland (AU)
  • Oslo University Hospital (NO)
Corresponding author
Llorente, Alicia
Venue
British Journal of Cancer
Published
2021-11-22
Volume
126
Issue
3
Pages
331-350
ISSN
  • 0007-0920 (ISSN-L)
  • 1532-1827
OpenAlex
W3217233110
Cited by
130
References
243
Citations by year
2026: 27 · 2025: 25 · 2024: 36 · 2023: 29 · 2022: 13
FWCI
2.13
Type
journal article
Language
en
Open access
Locations
  • British Journal of Cancer (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, cc-by)
  • NORA - Norwegian Open Research Archives (submittedVersion, cc-by)
  • Zaguan (Universidad de Zaragoza) (submittedVersion, cc-by)
Funders
Latvijas Zinātnes Padome
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Prostate Cancer Treatment and Research
Keywords
extracellular vesicles, prostate cancer, liquid biopsy, tumor markers, vesicle isolation, tumor microenvironment, precision medicine
MeSH terms
Extracellular Vesicles, Cell-Free Nucleic Acids, Liquid Biopsy, Animals, Humans, Male, Neoplastic Cells, Circulating, Prostatic Neoplasms, Biomarkers, Tumor, Early Detection of Cancer, Precision Medicine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review